PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer
Not Applicable
- Conditions
- Advanced Gastric Adenocarcinoma
- Interventions
- First Posted Date
- 2019-11-22
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04174339
- Locations
- 🇨🇳
Rongbo Lin, Fuzhou, China
POF Versus FOLFOX Plus IP Paclitaxel in AGC
Phase 2
- Conditions
- Gastric Cancer
- Interventions
- Drug: POFDrug: FOLFOX plus PAC(ip)
- First Posted Date
- 2019-11-07
- Last Posted Date
- 2019-11-07
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 260
- Registration Number
- NCT04155671
Neoadjuvant POF in the Treatment of Locally Advanced Gastric Cancer
- First Posted Date
- 2019-11-04
- Last Posted Date
- 2019-11-04
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04149015
Study of the Apatinib Combine With POF Versus POF in Gastric Cancer
- First Posted Date
- 2019-10-09
- Last Posted Date
- 2019-10-09
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 116
- Registration Number
- NCT04121039
- Locations
- 🇨🇳
Rongbo Lin, Fuzhou, Fujian, China
Apatinib Plus Sintilimab in Advanced Gastric Cancer Refractory to at Least Two Previous Chemotherapy Regimens
Phase 2
- Conditions
- Advanced Metastatic Gastric Cancer
- Interventions
- First Posted Date
- 2019-09-13
- Last Posted Date
- 2019-09-13
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04089657
Effects of Anesthesia on Tumor Immunity and Insulin Resistance During Perioperative Period
Not Applicable
Completed
- Conditions
- AnesthesiaTumor ImmunityCervical CancerCarbohydrate
- Interventions
- Other: oral carbohydrate liquid
- First Posted Date
- 2019-03-13
- Last Posted Date
- 2019-03-13
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT03872635
- Locations
- 🇨🇳
Fuqing Zhang, Fuzhou, Fujian, China
🇨🇳Mengxia Yao, Fuzhou, Fujian, China
Apatinib Combined With POF for Second-line Treatment of Gastric Adenocarcinoma
- First Posted Date
- 2018-12-27
- Last Posted Date
- 2019-05-10
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 26
- Registration Number
- NCT03788174
- Locations
- 🇨🇳
Rongbo Lin, Fuzhou, China
A Randomized Phase III Study Comparing POF With SOX/CAPOX/FOLFOX as a Postoperative Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer
Phase 3
- Conditions
- Gastric Cancer Stage III
- Interventions
- Drug: POFDrug: CAPOX/SOX/FOLFOX
- First Posted Date
- 2018-12-27
- Last Posted Date
- 2019-10-16
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 600
- Registration Number
- NCT03788226
- Locations
- 🇨🇳
Rongbo Lin, Fuzhou, China
EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC
Phase 2
- Conditions
- EGFR Gene Mutation
- Interventions
- First Posted Date
- 2018-10-25
- Last Posted Date
- 2018-10-25
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT03720873
- Locations
- 🇨🇳
Fujian cancer hospital, Fuzhou, Fujian, China
Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal Adenocarcinoma
Phase 3
Withdrawn
- Conditions
- Colorectal Adenocarcinoma
- Interventions
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2021-03-08
- Lead Sponsor
- Fujian Cancer Hospital
- Registration Number
- NCT03708536
- Locations
- 🇨🇳
Rongbo Lin, Fuzhou, Fujian, China
© Copyright 2025. All Rights Reserved by MedPath